Enterprise Value
415.8M
Cash
340.4M
Avg Qtr Burn
-12.12M
Short % of Float
253.77%
Insider Ownership
8.55%
Institutional Own.
82.16%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BT8009 (Nectin-4) Details Solid tumor/s, Cancer, Urothelial cancer, Bladder cancer | Phase 2/3 Initiation | |
BT7480 (Nectin-4 CD137, TICA) Details Solid tumor/s, Cancer | Phase 1/2 Update | |
BT1718 (MT1-MMP) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 1/2 Update | |
BT5528 (EphA2) Details Solid tumor/s | Phase 1/2 Update |